E-ISSN 2602-3164
Ahead of Print | DOI: 10.14744/ejmi.2019.62618

Development of venous thromboembolism in patients with hereditary thrombophilic risk factors and evaluation of genetic and biochemical parameters affecting development of venous thromboembolism

Ufuk Turan Kursat Korkmaz1, Ayhan Cetinkaya2, Ahmet Yuksel1, Yusuf Velioglu1, Erhan Renan Ucaroglu1, Ali Osman Arslan3, Kemalettin Erdem1, Selma Duzenli3, Bahadir Daglar1
1Department of Cardiovascular Surgery, Bolu Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey, 2Department of Physiology, Bolu Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey, 3Department of Medical Genetics, Bolu Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey

Objective: To evaluate patients diagnosed with venous thromboembolism (VTE) in terms of hereditary thrombophilic risk factors and to assess genetic and biochemical factors affecting the development of VTE. Methods: Sixty patients with VTE and 23 control subjects without VTE were retrospectively evaluated. Prevalence of thrombophilic risk factors and parameters like demographic data, clinical follow-up duration were examined with genetic, biochemical and radiological investigations. Results: Mutations were detected in the genes of Factor V Leiden in 37.4%, Factor II in 13.4%, Methylenetetrahydrofolate reductase C677 in 47.5%, Methylenetetrahydrofolate reductase A1298C in 53.3%, Plasminogen activator inhibitor-1 in 31.6%, Angiotensin converting enzyme in 39.0%, and Factor V H1299R in 8.3% of patients. Protein C deficiency was detected in 25 patients (41.7%), free Protein S deficiency was detected in 25 patients (41.7%) in study group and 3 subjects (13.0%) in control group, and this difference was statistically significant (p=0.023). Antithrombin III deficiency was detected in 1 patient (1.7%) in study group. Elevated homocysteine was higher in study group compared to controls, and the difference was statistically significant (p=0.02). Conclusion: Determination of hereditary risk factors in VTE patients will provide family members who have hereditary risk factors, but did not suffer attack to be protected against thromboembolic attacks by taking simple measures against acquired factors.


Cite This Article

Korkmaz U, Cetinkaya A, Yuksel A, Velioglu Y, Ucaroglu E, Arslan A, Erdem K, Duzenli S, Daglar B. Development of venous thromboembolism in patients with hereditary thrombophilic risk factors and evaluation of genetic and biochemical parameters affecting development of venous thromboembolism. ejmi. ; (): -

Corresponding Author: Yuksel A.